Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Sunday, November 1, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Complement-Based Drug Development Summit leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Sreoshi Chatterjee
  • Page 27

Author

Sreoshi Chatterjee 452 posts 0 comments

Select Medical Holdings and Dignity Health asserts integration of Concentra and HealthWorks

Feb 2, 2018
Select Medical Holdings Corporation and Dignity Health asserted the completion of the transaction to combine Concentra Group with U.S HealthWorks, Inc, a subsidiary of Dignity Health …
Read More...

FDA concedes IND for Imago BioScience’s IMG-7289 in the U.S

Feb 2, 2018
Clinical-stage pharmaceutical company, Imago BioSciences developing novel therapies for hematological and inflammatory diseases asserted FDA's acceptance of their Investigational New…
Read More...

Allergan asserts FDA’s approval for ssNDA for AVYCAZ

Feb 2, 2018
Allergan plc asserted that the U.S Food and Drug Administration has approved Allergan's  supplemental New Drug Application to augment the use of AVYCAZ (ceftazidime and avibactam) to…
Read More...

Lazarex states New FDA guidance issued

Feb 2, 2018
With a view to permit cancer patients access to potentially life-saving treatments, Lazarex Cancer Foundation's push for FDA issuing new FDA guidelines was taken into account by the…
Read More...

Syndax Pharmaceuticals affirms Oncology Clinical Trial venture with AstraZeneca

Feb 2, 2018
Clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, Syndax Pharmaceuticals ventured into new Clinical collaboration with AstraZeneca to…
Read More...

Panacea Pharmaceuticals enrolls patient for PAN-301-1 Phase 1 Clinical Trial

Feb 2, 2018
Panacea Pharmaceuticals, a clinical stage bio-pharmaceutical company developing novel biologically--targeted cancer therapies and diagnostics declared the enrollment of patient in an…
Read More...

China’s Transcatheter MitralStitch mitral valve repair system completed

Feb 2, 2018
Yunnan Fuwai Hospital declares successful completion of clinical case of MitralStitch mitral valve repair system. The operation was jointly conducted by the team of Professor Pan…
Read More...

TVA Medical’s everlinQ endoAVF System exhibits positive Clinical results

Feb 2, 2018
It is noteworthy that TVA Medical's everlinQ endoAVF System exhibited positive Clinical results using the everlinQ endoAVF System. An international meta-analysis of clinical experience…
Read More...

Ambry Genetics partners Invicro to extend customized genomics and imaging services

Feb 1, 2018
Ambry Genetics and Invicro partner to offer customized genomics and imaging services for the pharmaceutical and biotechnology industry, exhibiting profound emphasis on Oncology and…
Read More...

NuvOx Pharma concedes FDA’s approval to Phase II Clinical Trial

Feb 1, 2018
FDA permits a Phase II Clinical Trial in 60 stroke patients, NuvOx Pharma announced FDA approval to proceed to test its investigational drug product, dodecafluoropentane emulsion…
Read More...
Prev Next
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
8th RNAi-Based Therapeutics Summit
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
RNA-Targeted Drug Discovery & Development Summit
RNA-Based Therapeutics & Vaccines Summit South Korea
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Adalvo Acquires Enzene’s Romiplostim Biosimilar Programme
  • Appian and PSI CRO Partner to Bring AI Into Clinical Trials
  • Pfizer Partners With Edison Scientific to Accelerate AI-Driven Drug Research
  • Dren Bio Raises $350M to Advance Experimental Blood Cancer Drug
  • Glenmark Opens Major US Pharmaceutical Distribution Center in Pennsylvania

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.